The analysis of 3 dozen studies found similarities and differences in motivating factors for and against clinical trial ...

Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term trials and ...

Stephen Speicher, MD, and Kate Estep, from Flatiron Health, discuss the future of oncology care with artificial intelligence ...

The move would align prescription costs in the US with the costs of other countries, according to the administration.

A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve ...

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian ...

Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in ...

Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of ...

Experts discuss lessons learned from implementing lipoprotein(a) (Lp[a]) testing in health care systems, how health systems can prioritize patients for testing based on the National Lipid ...

Panelists discuss how treatment success in immunoglobulin A (IgA) nephropathy extends beyond clinical trial end points to encompass sustained proteinuria reduction, stable kidney function, symptom ...

Panelists discuss how immunoglobulin A (IgA) nephropathy progression creates escalating economic burdens for patients through direct health care costs, lost productivity, increasing medication needs, ...